Development and validation of RP-HPLC-UV method for simultaneous determination of buparvaquone, atenolol, propranolol, quinidine and verapamil: a tool for the standardization of rat in situ intestinal permeability studies.
A simple, sensitive and specific reversed phase high performance liquid chromatographic (RP-HPLC) method with UV detection at 251 nm was developed for simultaneous quantitation of buparvaquone (BPQ), atenolol, propranolol, quinidine and verapamil. The method was applicable in rat in situ intestinal permeability study to assess intestinal permeability of BPQ, a promising lead compound for Leishmania donovani infections. The method was validated on a C-4 column with mobile phase comprising ammonium acetate buffer (0.02 M, pH 3.5) and acetonitrile in the ratio of 30:70 (v/v) at a flow rate of 1.0 ml/min. The retention times for atenolol, quinidine, propranolol, verapamil and BPQ were 4.30, 5.96, 6.55, 7.98 and 8.54 min, respectively. The calibration curves were linear (correlation coefficient > or =0.996) in the selected range of each analyte. The method is specific and sensitive with limit of quantitation of 15 microg/ml for atenolol, 0.8 microg/ml for quinidine, 5 microg/ml for propranolol, 10 microg/ml for verapamil and 200 ng/ml for BPQ. The validated method was found to be accurate and precise in the working calibration range. Stability studies were carried out at different storage conditions and all the analytes were found to be stable. This method is simple, reliable and can be routinely used for accurate permeability characterization.
Venkatesh
Gantala
G
Centre for Drug Research, Universiti Sains Malaysia, 11800 Penang, Malaysia. venku16@yahoo.com
Ramanathan
S
S
Mansor
S M
SM
Nair
N K
NK
Sattar
Munavvar Abdul
MA
Croft
Simon L
SL
Navaratnam
V
V
D000818:Animals; D000981:Antiprotozoal Agents / Q000032:analysis / Q000737:chemistry / Q000493:pharmacokinetics; D001262:Atenolol / Q000032:analysis* / Q000737:chemistry / Q000493:pharmacokinetics; D002021:Buffers; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004355:Drug Stability; D006863:Hydrogen-Ion Concentration; D007413:Intestinal Mucosa / Q000187:drug effects; D008297:Male; D015394:Molecular Structure; D009285:Naphthoquinones / Q000032:analysis* / Q000737:chemistry / Q000493:pharmacokinetics; D010477:Perfusion; D010539:Permeability / Q000187:drug effects; D011433:Propranolol / Q000032:analysis* / Q000737:chemistry / Q000493:pharmacokinetics; D011802:Quinidine / Q000032:analysis* / Q000737:chemistry / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013056:Spectrophotometry, Ultraviolet / Q000379:methods*; D014700:Verapamil / Q000032:analysis* / Q000737:chemistry / Q000493:pharmacokinetics
D000981:Antiprotozoal Agents; D002021:Buffers; D009285:Naphthoquinones; C046326:buparvaquone; D001262:Atenolol; D011433:Propranolol; D014700:Verapamil; D011802:Quinidine